Consequently, there is a need for new specific targets for the therapy of anti-ErbB2-resistant breast cancer, including Triple Negative Breast Cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor and ErbB2. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.